Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)
Trial · NCT03359356
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 | Placebo Then Dupilumab | -6.3 | Standard Deviation 4.2 | score on a scale | |
| Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24 | Dupilumab | 2.3 | Standard Deviation 3 | score on a scale | |
| Change From Week 24 in the SALT Score at Week 48 | Placebo Then Dupilumab | -6.3 | Standard Error 4.2 | score on a scale | |
| Change From Week 24 in the SALT Score at Week 48 | Dupilumab | 2.3 | Standard Error 3 | score on a scale | |
| Change From Baseline in the SALT Score at Week 48 | Placebo Then Dupilumab | -6.3 | Standard Error 4.2 | score on a scale | |
| Change From Baseline in the SALT Score at Week 48 | Dupilumab | 2.3 | Standard Error 3 | score on a scale | |
| Number of Patients Achieving at Least 50% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-50) at Weeks 24 and 48 Compared to Baseline | Placebo Then Dupilumab | Week 24 | 0 | Participants | |
| Number of Patients Achieving at Least 50% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-50) at Weeks 24 and 48 Compared to Baseline | Dupilumab | Week 24 | 4 | Participants | |
| Number of Patients Achieving at Least 50% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-50) at Weeks 24 and 48 Compared to Baseline | Placebo Then Dupilumab | Week 48 | 3 | Participants | |
| Number of Patients Achieving at Least 50% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-50) at Weeks 24 and 48 Compared to Baseline | Dupilumab | Week 48 | 9 | Participants | |
| Number of Patients Achieving at Least 75% Improvement in SALT-75 at Weeks 24 and 48 | Placebo Then Dupilumab | Week 24 | 0 | Participants | |
| Number of Patients Achieving at Least 75% Improvement in SALT-75 at Weeks 24 and 48 | Dupilumab | Week 24 | 2 | Participants | |
| Number of Patients Achieving at Least 75% Improvement in SALT-75 at Weeks 24 and 48 | Placebo Then Dupilumab | Week 48 | 1 | Participants | |
| Number of Patients Achieving at Least 75% Improvement in SALT-75 at Weeks 24 and 48 | Dupilumab | Week 48 | 6 | Participants | |
| Number of Patients Achieving at Least 90% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-90) at Weeks 24 and 48 | Placebo Then Dupilumab | Week 24 | 0 | Participants | |
| Number of Patients Achieving at Least 90% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-90) at Weeks 24 and 48 | Dupilumab | Week 24 | 1 | Participants | |
| Number of Patients Achieving at Least 90% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-90) at Weeks 24 and 48 | Placebo Then Dupilumab | Week 48 | 1 | Participants | |
| Number of Patients Achieving at Least 90% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-90) at Weeks 24 and 48 | Dupilumab | Week 48 | 4 | Participants | |
| Change in Alopecia Areata Symptom Impact Scale (AASIS) | Placebo | Week 24 | 10.25 | Standard Error 20.29 | score on a scale |
| Change in Alopecia Areata Symptom Impact Scale (AASIS) | Dupilumab | Week 24 | 0.64 | Standard Error 22.27 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03359356/results